Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Castle Biosciences Inc
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Services-Medical Laboratories
Prev close 35.53 · gapped below the open, then crossed back over prior close. High/low 35.72 at 4:00 pm ET, 33.70 at 8:45 am ET.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“Our revenue for our test reports provided for patients covered by Medicare as a percentage of total revenue, was 44% and 47% for the years ended December 31, 2025 and 2024, respectively.”
$151M relationship
basisCSTL fy2025 · closed 2025-12 $344M
FILING10-K0001628280-26-012272cik 0001447362
“On March 26, 2024 (the "Closing Date"), we entered into a loan and security agreement, as amended in April 2025 (the "2024 LSA"), by and between us, our wholly owned subsidiary, Castle Narnia Real Estate Holding 1, LLC and Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (the "Lender").”
FILING10-K0001628280-26-012272cik 0001447362
“For example, we license certain intellectual property from WUSTL that is incorporated into DecisionDx-UM.”
FILING10-K0001628280-26-012272cik 0001447362
“For example, we have a U.S. Federal Supply Schedule contract with the Veterans Health Administration covering tests with the exception of DecisionDx-UM.”
FILING10-K0001628280-26-012272cik 0001447362
“Although we are an in-network participating provider with some commercial third-party payors, including several Blue Cross Blue Shield plans, and certain large, national commercial third-party payors, including Aetna, other commercial third-party payors have issued non-coverage policies that currently categorize our tests as experimental or investigational.”
FILING10-K0001628280-26-012272cik 0001447362
“Palmetto's MolDX program oversees MAAA tests that are reported from our Phoenix laboratory and Noridian is the MAC responsible for administering Medicare claims for test reports issued by our Phoenix laboratory.”
FILING10-K0001628280-26-012272cik 0001447362
“Novitas is the MAC responsible for administering Medicare claims for test reports issued by our Pittsburgh laboratory.”
FILING10-K0001628280-26-012272cik 0001447362
“Palmetto's MolDX program oversees MAAA tests that are reported from our Phoenix laboratory and Noridian is the MAC responsible for administering Medicare claims for test reports issued by our Phoenix laboratory.”
FILING10-K0001628280-26-012272cik 0001447362
“In June 2025, we entered into a collaboration and license agreement with SciBase Holding AB ("SciBase") to develop and commercialize diagnostic tests for dermatologic diseases, beginning with atopic dermatitis.”
FILING10-K0001628280-26-012272cik 0001447362
“Palmetto issued a final expanded test-specific LCD for DecisionDx-Melanoma, effective November 22, 2020.”
FILING10-K0001628280-26-012272cik 0001447362
“All of our MAAA tests, excluding our recently launched AdvanceAD-Tx test, have been granted Advanced Diagnostic Laboratory Test ("ADLT") status by the Centers for Medicare and Medicaid ("CMS") which means each test has demonstrated that (i) when combined with an empirically derived algorithm, it yields a result that predicts the probability a specific individual patient will develop a certain condition or conditions, or will respond to a particular therapy or therapies; and (ii) it provides new clinical diagnostic information that cannot be obtained from any other test or combination of tests.”
FILING10-K0001628280-26-012272cik 0001447362
“We procure certain reagents, equipment, chips/cards and other materials used to perform our tests from sole suppliers such as ThermoFisher Scientific, Inc., Promega and Qiagen, Inc.”
FILING10-K0001628280-26-012272cik 0001447362
“We procure certain reagents, equipment, chips/cards and other materials used to perform our tests from sole suppliers such as ThermoFisher Scientific, Inc., Promega and Qiagen, Inc.”
FILING10-K0001628280-26-012272cik 0001447362
“We procure certain reagents, equipment, chips/cards and other materials used to perform our tests from sole suppliers such as ThermoFisher Scientific, Inc., Promega and Qiagen, Inc.”
FILING10-K0001628280-26-012272cik 0001447362
Watchlist prices, news filtered to it, and its next report on your desk.
Castle Biosciences Inc has 6 disclosed suppliers and 8 disclosed customers. Each one is named in an SEC filing, either Castle Biosciences Inc’s own annual report or the counterparty’s, and carries the sentence that discloses it.
CSTL (Castle Biosciences Inc) has 6 disclosed suppliers and 8 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: QGEN +0.15%, in industrials & materials.